Scinai Immunotherapeutics (SCNI) Total Current Liabilities (2017 - 2025)

Scinai Immunotherapeutics has disclosed Total Current Liabilities across 9 years of filings, most recently posting $7.9 million for Q4 2025.

• Total Current Liabilities for Q4 2025 came in at $7.9 million, up 336.38% year-over-year; the trailing twelve-month figure through Dec 2025 was $7.9 million (up 336.38% YoY), and the FY2025 annual result was $7.9 million, up 336.38% from the prior year.
• Total Current Liabilities came in at $7.9 million for Q4 2025 at Scinai Immunotherapeutics, up from $2.1 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $21.8 million in Q3 2021 to a low of $1.4 million in Q3 2024.
• The 5-year median for Total Current Liabilities is $1.9 million (2024), against an average of $4.0 million.
• Across the five-year window, Total Current Liabilities surged 571.28% in 2021 and slumped 93.2% in 2022, its largest moves.
• Scinai Immunotherapeutics' Total Current Liabilities stood at $2.4 million in 2021, then dropped by 4.34% to $2.3 million in 2022, then retreated by 23.87% to $1.8 million in 2023, then climbed by 1.46% to $1.8 million in 2024, then soared by 336.38% to $7.9 million in 2025.
• The last three Total Current Liabilities figures came in at $7.9 million (Q4 2025), $2.1 million (Q2 2025), and $1.8 million (Q4 2024), per Business Quant data.